Do braf inhibitors cause Acute Kidney Injury
Do braf (V-RAF murine sarcoma viral oncogene homolog B) inhibitors cause AKI?
BRAF is a protooncogene involved in cell signaling that, when mutated, has been associated with development of a number of other malignancies.
Braf inhibitors are V-RAF murine sarcoma viral oncogene homolog B.
Vemurafenib is associated with ATN, which can be associated with proteinuria (~500 g/day), and usually resolves with drug discontinuation. Reintroduction with dose reduction may cause recurrent AKI.
Vemurafenib-induced nephrotoxicity may also include Fanconi syndrome and Sweet syndrome (also called acute febrile neutrophilic dermatosis; it is an uncommon skin condition characterized by fever and inflamed or blistered skin and mucosal lesions).
Dabrafenib is associated with a lower incidence of AKI, although when combined with trametinib, an mitogen-activated protein kinase kinase (MEK) inhibitor, AKI incidence increases.
The manifestations involving the kidneys are more commonly seen with dabrafenib are hyponatremia, hypokalemia, and hypophosphatemia.
BRAF inhibitor–induced AKI causes both tubular and interstitial damage.